Is Bicycle Therapeutics plc (NASDAQ:BCYC) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Bicycle Therapeutics plc at current levels.
Cash-covered clinical biotech trading below book, with a Phase 2/3 nectin-4 readout that could re-rate this into a takeout candidate.
Where BCYC is headed
Bicycle Therapeutics sits at $304M market cap trading at 0.55x book, with an EV/EBITDA of 1.0 that tells you the market has effectively written the equity down to cash and change. This is a company whose lead asset, zelenectide pevedotin, is a bicyclic peptide-drug conjugate going after nectin-4 in urothelial cancer, the same target Pfizer paid $43 billion for when it bought Seagen for Padcev. If the Duravelo-2 pivotal data in 2027 shows a cleaner tolerability profile than Padcev at competitive response rates, this is not a $300M company. It is a $2-3B takeout, minimum, because every major oncology franchise wants a next-generation ADC that can be dosed longer without the peripheral neuropathy that limits Padcev.
Read the full Compass Direction on BCYC
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $4.35).
See the full BCYC analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Bicycle Therapeutics plc (NASDAQ:BCYC) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Bicycle Therapeutics plc at current levels. Cash-covered clinical biotech trading below book, with a Phase 2/3 nectin-4 readout that could re-rate this into a takeout candidate.
What is BCYC's Compass Score?
Bicycle Therapeutics plc scores 77/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for BCYC?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the BCYC page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.